This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
If you’re in the BioPharma and Pharmaceutical industries, your most valuable resource isn’t just the latest breakthrough drug or cutting-edge technology. Enter the world of executive search firms, headhunters, and recruiters specializing in the BioPharma and Pharmaceutical industries. Let’s dive in.
Their focus on values and work ethics makes them a standout partner in the pursuit of top CRO talent. With expertise in connecting organizations with top-tier executive talent, "Alliance International Services" is a trusted partner for businesses seeking CROs who can drive success in today's competitive landscape.
Fuelling Growth: Strategic Investments, Acquisitions, and Expansions Samsung Biologics unveiled plans to expand capacity and geographic reach by initiating the construction of Bio Campus II with a $6 billion investment scheduled to begin operations in 2025 while completing its CGMP antibody-drug conjugate manufacturing facility within 2024.
We organize all of the trending information in your field so you don't have to. Join 61,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Biopharma 
130 
Let's personalize your content